Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

PHASE3TerminatedINTERVENTIONAL
Enrollment

667

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

December 31, 2009

Conditions
Benign Prostatic Hypertrophy
Interventions
DRUG

Cetrorelix 78 mg + 78 mg

DRUG

Cetrorelix 78 mg + 52 mg

DRUG

Placebo

Trial Locations (68)

1756

National Oncological Hospital, Sofia

10016

New York University School of Medecine, New York

University Urology, New York

11530

Urological Surgeons of Long Island, Clinical Research Division, Garden City

11706

Medical & Clinical Research Associates, Bay Shore

12601

Hudson Valley Urology, Poughkeepsie

12627

ClinPharm International GmbH Prufzentrum Berlin, Berlin

20770

Myron I. Murdock M.D. LLC, Greenbelt

28025

Northeast Urology Research, Concord

29572

Carolina Urologic Research Center, Myrtle Beach

31904

Southwestern Medical Research Institute, Columbus

32114

Atlantic Urological Associates, Daytona Beach

32308

Southeastern Research Group, Tallahassee

33180

South Florida Medical Research, Aventura

33761

Tampa Bay Medical Research, Clearwater

34237

Florida Urologist Specialists, Sarasota

34474

Florida Healthcare Research, Ocala

35801

Medical Affiliated Research Center, Inc., Huntsville

37232

Vanderbilt University medical Center, Nashville

39104

ClinPharm International GmbH Prufzentrum Magdeburg, Magdeburg

42003

Four Rivers Clinical Research, Paducah

44787

ClinPharm International GmbH Prufzentrum Bochum, Bochum

46825

Northeast Indiana Research, LLC, Fort Wayne

47713

Welborn Clinic, Evansville

48081

Michigan Institute of Urology, Saint Clair Shores

60596

ClinPharm International GmbH Prufzentrum Frankfurt, Frankfurt

60611

Northwestern University Feinberg School of Medecine, Chicago

63110

Washington University, St Louis

63136

Metropolitan Urological Specialists, St Louis

66211

Kansas City Urology Care, Overland Park

68114

Quality Clinical Research, Omaha

72901

Urology Group of Westrn Arkansas, Fort Smith

73008

Parkhurst Research Oganization Inc., Bethany

75231

Urology Clinics of North Texas, Dallas

77030

Institute and the Texas Prostate Center, Houston

78229

Urology San Antonio Research, PA, San Antonio

78404

Corpus Christi Urology Group, Corpus Christi

80012

Urology Research Options, Aurora

80220

Genitourinary Surgical Consultants, Denver

87109

Urology Group Of New Mexico, Albuquerque

90505

Western Clinical Research, Inc., Torrance

91356

West Coast Clinical Research, Tarzana

92103

William G. Moseley, San Diego

92653

South Orange County Medical Research Center, Laguna Hills

92660

California Professionnal Research, Newport Beach

98043

Integrity Medical Research, Mountlake Terrace

80045-0510

Urologic Oncology, Aurora

06762

Connecticut Clincal Research Center, Middlebury

33125-1693

Miami VACM, Miami

08060

Delaware Valley Urology, LLC, Woodlane

75390-9110

University of Texas Southwestern Medical Center, Department of Urology, Dallas

V1Y 2H4

Southern Interior Medical Research Inc., Kelowna

V3V 1N1

Andreou Research Inc., Surrey

V8T 5G1

Can-Med Clinical Reserach Inc., Victoria

L4M 7G1

The Male / FemaleHealth and Research Center, Barrie

K7L 3J7

Centre for Advanced Urological Research, Kingston

N2M 5N4

Urologic Associates, Urologic Medical Research, Kitchener

P1B 7K8

Canada Place Building, North Bay

L6H 3P1

The Fe/Male Health Centers, Oakville

M5G 2M9

University Health Network Princess Margaret Hospital, Toronto

M6A 3B5

The Male Health Center, Toronto

J4V 2H3

Urology South Shore Research, Greenfield Park

H2X 3J4

CHUM, Hopital St-Luc, Montreal

H9R 3J1

Dynamik Research, Pointe-Claire

G1R 2J6

CRCEO, Québec

01067

ClinPharm International GmbH Prufzentrum Dresden, Dresden

02826

ClinPharm International GmbH Prufzentrum Gorlitz, Görlitz

04103

ClinPharm International GmbH Prufzentrum Leipzig, Leipzig

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AEterna Zentaris

INDUSTRY

NCT00449150 - Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) | Biotech Hunter | Biotech Hunter